Amsel Medical Signs $7.45M Phase III SBIR Contract

Amsel Medical Corporation today announces that it has been awarded an $7.45 million sole source, non-dilutive, small business innovative research (SBIR) Phase III contract by the United States Air Force. This award represents a significant milestone for the company and builds on successful prior AFWERX Phase I, Phase II and TACFI SBIR contracts with the U.S. Air Force. This contract will help accelerate the commercialization of Amsel’s breakthrough, SCureTO™, precision hemorrhage control solution for combat casualty care trauma. It is expected to provide a life and limb saving capability to the Department of the Air Force, Special Operations Command, and U.S. Department of Defense (DoD) in preparation for future “near peer” conflicts. Read more >>